News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal 3/22/2017
Novartis AG (NVS)'s Phase III Drug for Heart Failure Bombs Trial 3/22/2017
Poxel SAS Announces Positive Results For Thorough QT Safety Clinical Study Of Imeglimin 3/21/2017
NETRIS Pharma Starts Enrollment Of First Clinical Study To Evaluate Drug Candidate Targeting Dependence Receptors 3/21/2017
NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa 3/20/2017
BioLineRx Provides Update On Phase II Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia 3/17/2017
Karolinska Development AB Umecrine Cognition Announces First Patient Included In Clinical Phase Ib/IIa Study With GR3027 For Hepatic Encephalopathy 3/17/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/14/2017
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032 3/14/2017
Sanofi (SNY) And Voluntis Announce A Global Alliance To Deliver Digital Insulin Titration Solutions For People With Type II Diabetes 3/14/2017
Kiadis Pharma To Present Atir10 Phase II Trial Data In Late Breaking Abstract At The International Society For Cellular Therapy (ISCT) 2017 Annual Meeting 3/13/2017
TiGenix Announces Top-Line Phase I/II Results Of AlloCSC-01 In Acute Myocardial Infarction 3/13/2017
Selvita To Present New Data From Its Oncology Programs At The Upcoming AACR Annual Meeting 2017 3/13/2017
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017
Nature Cell Started Commercial Clinical Trials Phase I And II "ASTROSTEM," Stem Cell Drug For Alzheimer's Disease Treatment In U.S. 3/10/2017
REGiMMUNE Phase IIa Results Of RGI-2001, An Activator Of Invariant Natural Killer T Cells, Published In "Biology Of Blood And Marrow Transplantation" 3/10/2017
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease 3/10/2017
Bone Therapeutics Completes Recruitment Of 16 Patients In ALLOB Phase I/IIA Delayed-Union Study 3/9/2017
Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis 3/8/2017
Neurim Pharmaceuticals Release: Phase II Clinical Trial For Treatment Of Mild Alzheimer's Disease 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Abzena Inside Product For Neurodegenerative Conditions Moves Into Phase II Trial 3/6/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis 3/3/2017
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017
SELLAS Life Sci Announces Updated Positive Phase II Data Reinforcing Meaningful Clinical Benefit Of Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients 3/1/2017
NeuroDerm (NDRM) Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting 3/1/2017
Roche (RHHBY)'s Renal Success Spells Danger For All-Comer Studies 2/27/2017
Addex Therapeutics (ADXN.SW)'s ADX71149 Anti-Epileptic Effect Highlighted In Scientific Journal, Epilepsia 2/27/2017
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017
Minoryx Therapeutics Receives Orphan Drug Designation From The FDA For Its Lead Candidate MIN-102 2/22/2017
Immuron Completes Phase II NASH Clinical Trial Recruitment 2/21/2017
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation 2/21/2017
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
ASLAN Receives Orphan Drug Designation In Korea For Varlitinib (ASLAN001) In Biliary Tract Cancer 2/20/2017
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients 2/17/2017
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Biotron Limited (BIT:AU) Release: Commencement Of BIT225 Phase ll HIV-1 Clinical Trial 2/13/2017
MMJ PhytoTech Phase ll Clinical Trial For Treatment of Epilepsy Underway 2/13/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
CRT Pioneer Fund And Cardiff University Announce The Initiation Of The Phase II MONOCLE Study Of Tefinostat For The Treatment Of Chronic Myelomonocytic Leukaemia With Funding To Progress Further Development 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Immuron Announces First Patient Enrolled In Pediatric Fatty-Liver Phase II Trial 2/7/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test 2/6/2017
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome 2/6/2017
DBV Tech Announces Completion Of Enrollment Of Phase IIA Study Of Viaskin Milk For The Treatment Of Pediatric Eosinophilic Esophagitis 2/3/2017
Galapagos (GLPG.BR) Doses First Patient With Novel CF Corrector GLPG2222 2/2/2017
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017
TiGenix Enrolls First Patient iIn Phase Ib/IIa Clinical Trial Of Cx611 In Severe Sepsis 1/31/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Biomay AG Release: Company Reports Positive Results From A Second Phase Ilb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine Bm32 1/26/2017
4SC (VSC.F) Release: Overall Survival Benefit For Resminostat In First-Line Liver Cancer Study Subgroup 1/26/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017
ProMetic Life Sci (PFSCF.PK) Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome 1/24/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Sanifit Release: Biopharma Announces Enrollment Of First Patient In CaLIPSO – A Phase Ilb Study For The Treatment Of Cardiovascular Calcification In End-Stage-Renal-Disease Patients On Haemodialsis 1/23/2017
Prima Biomed (PRR.AX) Release: Company Commences Randomised Phase IIb Clinical Trial For IMP321 In Breast Cancer 1/20/2017
ProMetic Life Sci (PFSCF.PK) Releaase: European Commission (EC) Grants Orphan Drug Designation To Company's PBI-4050 Drug For The Treatment Of Alström Syndrome 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
BioLineRx Release: Pharma Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 1/17/2017
AiCuris Release: Pharma Announces Publication Of Phase 2 Clinical Trial Results Of Investigational Anti-Herpes Simplex Virus Agent Pritelivir In JAMA 1/17/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In Second-Line Biliary Tract Cancer In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Combination Study Of Fruquintinib With Iressa (Gefitinib) In First-Line Non-Small Cell Lung Cancer 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Sulfatinib Phase II Study In 2nd Line BTC In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Combination Study In 1st-Line NSCLC 1/16/2017
Shionogi Release: Pharma Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 1/12/2017
MorphoSys AG Release: Company Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients With Type 2 Diabetes 1/12/2017
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout 1/11/2017
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients 1/10/2017
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017
Finding a Complementary Secondary Endpoint in Lupus Clinical Trials 1/10/2017
Galmed Pharmaceuticals Completes Patient Recruitment For ARREST Phase IIb NASH Study 1/9/2017
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017
Probiodrug AG Announces Completion Of Recruitment For The SAPHIR Phase 2a Study Of Glutaminyl Cyclase Inhibitor PQ912 In Early Alzheimer's Disease Patients 1/9/2017
TLC Biopharmaceuticals, Inc. Reports Results Of Phase 1/2 Clinical Trial Of TLC599 For Sustained Pain Relief In The Treatment Of Osteoarthritis Of The Knee 1/6/2017
US FDA Grants Orphan Drug Designation To YiSheng BioPharma's PIKA Rabies Vaccine 1/4/2017
Senhwa Biosciences CX-4945 Granted Orphan Drug Designation By The US FDA In Cholangiocarcinoma 1/4/2017
Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant (ESN364) In The Treatment Of Menopausal Hot Flashes 1/4/2017
Inventiva Announces Initiation Of Phase IIb Clinical Trial Of IVA337 For Treatment Of Non-Alcoholic Steatohepatitis (NASH) 1/3/2017
Bavarian Nordic (BAVA.CO) Initiates Trial Of CV301 In Combination With Nivolumab In Patients With Lung Cancer 12/29/2016
ThromboGenics NV (TBGNF) Announces Protocol Amendment To Phase II CIRCLE Trial Evaluating THR-409 (Ocriplasmin) In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 12/28/2016
Unexpected Clinical Results Cause Hansa Medical to Terminate Phase II With IdeS in Acquired TTP 12/21/2016
After Terminating BI-505 Phase II, BioInvent (BOVNF) Rebounds With Big Pharma Deal 12/21/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
GenSight Biologics Reports Sustained Visual Acuity Gain At 78 Weeks In Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 12/20/2016
Prima Biomed (PRR.AX) Receives UK Approval For AIPAC Study 12/20/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
Genticel Reports Final Results Of GTL001 Phase II Trial In HPV16/18-Infected Women 12/14/2016
Zealand Pharma  (ZEAL.CO) Initiates Phase IIa Clinical Trial With Dasiglucagon In A Dual-Hormone Artificial Pancreas System From Beta Bionics 12/13/2016
MorphoSys AG Starts Phase 2 Trial Of MOR208 In Combination With Idelalisib In Patients With Relapsed Or Refractory CLL Or SLL Previously Treated With A BTK Inhibitor 12/13/2016
PHARNEXT Presents Positive Exploratory Phase 2 Data From PXT864 At The 9th Clinical Trials On Alzheimer’s Disease (CTAD) Conference In San Diego, United States 12/13/2016
NovoCure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer 12/13/2016
NovoCure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Cancer 12/13/2016
Axovant (AXON) Unveils New Data Analysis Showing Addition Of Intepirdine To Standard Therapy May Help People With Alzheimer's Disease Maintain Independence Longer 12/12/2016
RedHill Biopharma (RDHL) Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis 12/12/2016
BioInvent (BOVNF) Terminates Current BI-505 Phase II Study 12/9/2016
Probiodrug AG Release: Innovative Phase II Study Design Of Glutaminylcyclase Inhibitor PQ91 In Early Alzheimer’s Disease 12/8/2016
Neovacs Obtains FDA “Fast Track” Designation For IFNa Kinoid In Lupus (SLE) 12/7/2016
TRANSGENE (ENX:TNG), UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016
Kiadis Pharma Presents Positive 1-Year Follow-Up Data Of Its Pivotal Phase II Trial With ATIR101 12/6/2016
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016 12/6/2016
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing 12/6/2016
ReNeuron Release: Reports Positive Results In Phase II Stroke Trial 12/5/2016
BioLineRx Presents Positive Phase 2a AML Study And Mechanism-Of-Action Data For BL-8040 Oncology Platform At American Society of Hematology 2016 12/5/2016
Poxel SAS Release: Ability To Delay Type 2 Diabetes Disease Progression By Preserving Beta Cell Mass Observed In New Imeglimin Data 12/5/2016
BiondVax Pharmaceuticals Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate Is Safe And Well Tolerated 11/29/2016
BerGenBio AS Reports Promising BGB324 Phase I/II Monotherapy Data In Patients With Lung Cancer At The EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016
Araim Pharmaeuticals Release: ARA 290 Obtains European Union Orphan Drug Designation For Prevention Of Graft Loss In Pancreatic Islet Transplantation 11/28/2016
Nanobiotix Provides Update On Global Development Of Lead Product NBTXR3 11/28/2016
Medivir (MVRBF) Announces That Janssen Has Initiated An Open-Label Phase IIb Study Of The 3DAA Combination Of Simeprevir, Odalasvir And AL-335 (JNJ-4178) 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
Opthea Completes Patient Enrolment In Phase 1/2A Wet AMD Clinical Trial 11/22/2016
Ability Pharma Initiates Phase 2 Combination Trial With ABTL0812 As First Line Therapy In Patients With Endometrial Or Squamous Lung Cancer Patients 11/22/2016
Mallinckrodt (MNK) Will Initiate Company-Sponsored Clinical Trial Of H.P. Acthar Gel In Treatment Of Amyotropic Lateral Sclerosis (ALS) 11/21/2016
ProMetic Life Sci (PFSCF.PK) Receives Clearance From Health Canada To Proceed With Its PBI-4050 Placebo-Controlled Phase 2 Clinical Trial In Patients With Metabolic Syndrome And Type 2 Diabetes 11/16/2016
Genexine Co. Ltd. Granted FDA Orphan Drug Designation For GX-H9 In Growth Hormone Deficiency 11/16/2016
Tiziana Life Sciences Plc Announces New Data With Foralumab, A Fully Human Anti-CD3 Antibody Being Developed As An Oral Therapy For NASH And Autoimmune Diseases 11/16/2016
Merck KGaA (MKGAF.PK)'s Atacicept Flops in Phase IIb Lupus Study But Firm Remains Upbeat 11/15/2016
Karolinska Development AB Company Modus Therapeutics’ Ongoing Clinical Study With Sevuparin In Sickle Cell Disease Expands To Include Adolescent Patients 11/15/2016
Zytoprotec GmbH Phase II Peritoneal Dialysis Study: Last Patient Out 11/14/2016
AstraZeneca PLC (AZN) Faces Another R&D Setback as Plans to File for Early Approval for Cancer Med are Scrapped 11/10/2016
Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients 11/8/2016
Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results Of ASN-002 Treatment Of Nodular Basal Cell Carcinoma (nBCC) 11/8/2016
FDA Slaps a Full Clinical Hold on BioInvent (BOVNF)'s Phase II Multiple Myeloma Study 11/8/2016
Neovacs Enrolls The First U.S. Patient In Phase IIb Study Of Ifna Kinoid For Treatment Of Systemic Lupus Erythematosus (SLE) 11/7/2016
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin 11/4/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
GENFIT (ALGFT): FDA Has Officially Cleared The IND To Proceed With Phase II Trial And Evaluate Elafibranor In PBC 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
One Out of the Two Reasons Allergan (AGN) Paid $640 Million for Vitae Pharma (VTAE) Just Flunked Mid-Stage Test 11/3/2016
Sanofi Genzyme (SNY) Release: Pivotal Phase 2/3 Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) To Begin In The UK 11/3/2016
BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-Of-Action Data For BL-8040 Oncology Platform At American Society of Hematology 2016 11/3/2016
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS 11/3/2016
Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December 11/3/2016
Helsinn And MEI Pharma (MEIP) Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting 11/3/2016
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 11/2/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Presents Phase II Data On The Safety And Efficacy Of Atacicept At The 2016 ACR/ARHP Annual Meeting 11/2/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Program: Enrollment In The Phase IIa Study Is Complete And Independent Safety Review Committee Again Recommends Go Ahead 10/27/2016
DBV Tech Announces Publication Of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study In The Journal Of Allergy And Clinical Immunology 10/27/2016
National Center for Child Health And Development Initiates Phase 1/2 Trial Of Green Cross' Idursulfase-Beta ICV For The Treatment Of Hunter Syndrome With Neurocognitive Decline 10/26/2016
Debiopharm Reaches Important Development Milestones For Its Staphylococcus-Selective Antibiotic Debio 1450 10/25/2016
Roche (RHHBY)'s Avastin Successor Flunks Key Study, Turns Hope to Tecentriq Instead 10/21/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Meets Primary And Secondary End Points In Metabolic Syndrome And Type 2 Diabetes Phase 2 Clinical Trial 10/20/2016
Sanifit Announces Initiation Of First Clinical Trial Of SNF472 In Patients With Calciphylaxis 10/20/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
FDA Slaps Hold on Regeneron (REGN), Teva (TEVA)'s Pain Drug Fasinumab 10/18/2016
Addex Therapeutics (ADXN.SW) To Conduct Phase IIa Proof Of Concept Study Of Dipraglurant In Focal Cervical Dystonia 10/17/2016
MorphoSys AG Presents Updated Clinical Results For MOR202 At Medical Conference 10/17/2016
Hua Medicine's GKA Diabetes Treatment Passes Proof-of-Concept Trial 10/17/2016
NeuroVive (NVP) Stock Craters After Discontinuing Acute Kidney Injury Program 10/13/2016
BIOCAD Biotechnology Company Announces The Start Of Phase 2 Clinical Trials Of An Innovative Drug To Treat Severe Psoriasis 10/13/2016
Synairgen (SNG.L) Stock Tanks After Partner AstraZeneca PLC (AZN) Halts Asthma Drug Trial 10/12/2016
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Significantly Reduces Liver Fibrosis In Patients With Alström Syndrome 10/12/2016
PharmaMar Announces Positive Results From Its Phase II Study With Lurbinectedin In BRCA 1/2 - Associated Metastatic Breast Cancer At The ESMO 2016 Congress 10/10/2016
Karolinska Development AB Portfolio Company Aprea Enrolls First Patients In Phase II Trial Of APR-246 In Ovarian Cancer 10/10/2016
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 2 Combination Trial Of PROSTVAC And Ipilimumab In Patients With Localized Prostate Cancer 10/10/2016
Bone Therapeutics Reports Positive Efficacy Data For The ALLOB Phase IIA Spinal Fusion Trial 10/5/2016
Theranexus Has Obtained An Orphan Drug Designation From The FDA For THN102 In The Treatment Of Narcolepsy 10/4/2016
TheraVida, Inc. Release: THVD-102 Demonstrates Promising Potential As An Orally Administered Treatment For Hyperhidrosis 10/3/2016
Quantum Genomics Corp. Reports Positive Top-Line Results From Phase IIa Trial Of QGC001 In Hypertension 9/30/2016
Neurim Pharmaceuticals Announces First Patients' Enrollments In ReCOGNITION - Phase II Clinical Trial Of Piromelatine For Mild Alzheimer's Disease 9/28/2016
Ipsen (IPN.PA) Announces Data Presentations Of Cabozantinib (Cabometyx), Lanreotide (Somatuline® Autogel®) And Telotristat Ethyl* At The European Society For Medical Oncology (ESMO) 2016 Congress 9/27/2016
Galapagos (GLPG.BR) Release: Endoscopic Improvements With Filgotinib Are Consistent With Clinical Remission Rates In Patients With Crohn's Disease 9/26/2016
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016
Nordic Nanovector: Safety Review Committee Supports Dose Escalation With Betalutin In Lymrit 37-01 Trial Pending Safety Data From Cohort Receiving Higher Pre-Dosing 9/23/2016
Fundación MAPFRE Presents The Results Of Personalized Cell Therapy For Treating Spinal Cord Injury 9/23/2016
ASIT Biotech Announces The Initiation Of A Phase IIa Clinical Study Of Its Second Product Candidate Hdm-ASIT+TM For House Dust Mite Rhinitis 9/22/2016
Bionomics Limited (BNO.AX) Announces Positive Results From Phase 2 Trial Of BNC210 In Generalized Anxiety Disorder 9/21/2016
DBV Tech Receives FDA Fast Track Designation For Viaskin Milk For The Treatment Of Cow’s Milk Protein Allergy 9/21/2016
BiondVax Pharmaceuticals Phase 2b European Trial: Last Patient Out 9/21/2016
BioLineRx Announces Initiation Of Phase 2a Trial Of BL-8040 In Combination With KEYTRUDA (Pembrolizumab) For Treatment Of Pancreatic Cancer 9/20/2016
NeuroDerm (NDRM) To Present ND0612 Data At 4th World Parkinson Congress Demonstrating Ease Of Use Of Mini-Pump Delivery System 9/19/2016
Astellas (ALPMY), Vical  (VICL)'s Experimental Herpes Vaccine Flunks Mid-Stage Test 9/19/2016
Teva (TEVA) Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease 9/19/2016
Celgene (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase 2 Radiance Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Celgene International Sárl (CELG) Release: Oral Ozanimod Efficacy And Safety Results At 2 Years From Phase II RADIANCE Trial Of Patients With Relapsing Multiple Sclerosis Presented At 32nd ECTRIMS 9/16/2016
Eisai Company (ESALY.PK) Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 9/15/2016
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Euroscreen S.A. Completes Enrollment In Phase II Trial Of Lead Candidate ESN364 In Menopausal Hot Flashes 9/14/2016
Foamix Pharma (FOMX) To Announce Topline Results In Phase 2 Clinical Trial Of FMX-103 Minocycline Topical Foam For Moderate-To-Severe Papulopustular Rosacea 9/9/2016
Medivir (MVRBF): Interim Results From Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level Of Efficacy In HCV Patients 9/9/2016
ErgoMed Completes Recruitment Of Phase lla Clinical Trial Of Lorediplon In Insomnia In Collaboration With Co-Development Partner Ferrer 9/8/2016
BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference 9/8/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer” 9/7/2016



//-->